This story first appeared in The Readout newsletter. Sign up for The Readout and receive STAT’s award-winning biotech news delivered straight to your inbox.
The need-to-know this morning
- Moderna earnings are here.
- Gilead Sciences reported earnings last night.
What biopharma leaders think of the new Trump era
My colleagues have gathered reactions from leaders across the biopharma industry about what a second Donald Trump presidency could mean. While Trump has positioned himself as business-friendly, he’s also criticized high drug costs. And in the late stages of his campaign, he embraced Robert F. Kennedy Jr., who’s signaled he wants to shake up to the FDA and other health agencies.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
